Skip to main content

ADVERTISEMENT

primary mediastinal B cell lymphoma

Research in Review
05/18/2017
JCP Editors
A new treatment for a rare B-cell malignancy provided an objective response rate of 41% in a clinical trial, published in Blood (published online May 10, 2017; doi:10.1182/blood-2016-12-758383). ----- Related...
A new treatment for a rare B-cell malignancy provided an objective response rate of 41% in a clinical trial, published in Blood (published online May 10, 2017; doi:10.1182/blood-2016-12-758383). ----- Related...
A new...
05/18/2017
Journal of Clinical Pathways